Management of a Patient with eGFR 60 mL/min/1.73 m²
A patient with an eGFR of 60 mL/min/1.73 m² requires immediate measurement of urine albumin-to-creatinine ratio (UACR) to determine risk stratification and guide all subsequent management decisions. 1
Immediate Diagnostic Steps
Measure UACR immediately – this single test is the most critical determinant of cardiovascular and kidney disease risk at this GFR level. 2 Without knowing the albuminuria status, you cannot properly risk-stratify or make evidence-based treatment decisions. 1
Consider confirming the eGFR with cystatin C measurement – approximately 23% of individuals with eGFR 45–59 mL/min/1.73 m² are misclassified when only creatinine-based equations are used, and serum creatinine substantially underestimates kidney dysfunction, especially in older adults, women, and persons with low muscle mass. 2
Risk Stratification Based on Albuminuria
The patient's risk category depends entirely on their UACR result 1:
Low risk: eGFR ≥60 mL/min/1.73 m² with UACR <3 mg/mmol (<30 mg/g) – technically this patient does not have CKD by current definitions 1
Moderate risk: eGFR ≥60 mL/min/1.73 m² with UACR 3-30 mg/mmol (30-299 mg/g) 1
High risk: eGFR ≥60 mL/min/1.73 m² with UACR >30 mg/mmol (≥300 mg/g) 1
Monitoring Frequency
If UACR is normal (<30 mg/g): Screen annually with eGFR and UACR. 3 This patient does not meet criteria for CKD and requires only annual surveillance. 1
If UACR is 30-299 mg/g (moderately increased): Monitor eGFR and UACR twice annually. 4, 3
If UACR is ≥300 mg/g (severely increased): Monitor eGFR and UACR twice annually. 4, 3
Blood Pressure Management
Target blood pressure <140/90 mmHg for all patients with diabetes and CKD. 3, 5 More recent evidence supports targeting <120/80 mmHg if tolerated to slow CKD progression. 2
If UACR ≥30 mg/g, initiate an ACE inhibitor or ARB as first-line antihypertensive therapy, titrated to the highest tolerated dose. 3, 6 This recommendation is strongly supported (Grade A evidence) for patients with UACR ≥300 mg/g and eGFR <60 mL/min/1.73 m². 3
Do not use ACE inhibitors or ARBs for primary prevention in patients with normal blood pressure, normal UACR (<30 mg/g), and normal eGFR. 3, 6
Monitor serum creatinine and potassium periodically when using ACE inhibitors or ARBs. 3 Do not discontinue these medications for mild to moderate increases in serum creatinine (≤30%) in the absence of volume depletion. 3, 6
SGLT2 Inhibitor Therapy
For patients with type 2 diabetes and UACR ≥200 mg/g, initiate an SGLT2 inhibitor (empagliflozin, dapagliflozin, or canagliflozin) to reduce CKD progression and cardiovascular events. 4, 3, 2 This recommendation applies even at eGFR 60 mL/min/1.73 m² and remains valid down to eGFR ≥20 mL/min/1.73 m². 4, 3
SGLT2 inhibitors are recommended for most adults with established CKD irrespective of type 2 diabetes status, heart failure status, sex, gender, or ethnicity, provided they meet the albuminuria threshold. 1
Glucose Control (if Diabetic)
Optimize glucose management to reduce the risk or slow CKD progression. 4, 3 However, hemoglobin A1c targets should be individualized based on the patient's overall clinical context. 4
Cardiovascular Risk Reduction
Initiate statin therapy for cardiovascular risk reduction in all Stage 3A CKD patients. 2 Cardiovascular risk factors should be assessed at least annually, including dyslipidemia, hypertension, smoking, family history of premature coronary disease, and presence of albuminuria. 6
Nephrotoxic Avoidance
Avoid nephrotoxic medications including NSAIDs, certain antibiotics, and iodinated contrast agents whenever possible. 2 Preserve veins suitable for vascular access if hemodialysis may be needed in the future. 7
Dietary Considerations
Protein restriction is not recommended at this level of kidney function. For patients with non-dialysis-dependent stage 3 or higher CKD, dietary protein intake should be a maximum of 0.8 g/kg body weight per day (the recommended daily allowance). 4
Specialist Referral
Nephrology referral is not routinely indicated at eGFR 60 mL/min/1.73 m² unless there are complicating factors such as rapidly declining kidney function, uncertain etiology of kidney disease, difficult management issues, or UACR >60 mg/mmol (>500 mg/g). 8, 6
Common Pitfalls
The most critical error is failing to measure albuminuria – without this information, you cannot properly assess risk or guide therapy. 2 Additionally, do not assume this patient has CKD if their UACR is normal; an eGFR of 60 mL/min/1.73 m² alone, particularly in older adults, may represent age-related decline rather than disease. 1, 9